Global ANTI-CD19 ANTIBODY Market 2018 Key Players: CRISPR Therapeutics, Juno Therapeutics, MorphoSys, MacroGenics, TCR2 Therapeutics, Novimmune.

ANTI-CD19 ANTIBODY Market:

WiseGuyReports.com adds “ANTI-CD19 ANTIBODY Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting” reports to its database.

Executive Summary

The comprehensive list of anti-CD19 antibody that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of anti-CD19 antibody pipeline products that are in Phase 3, Phase 2, Phase 1, preclinical and discovery across different indications. This report also provides comprehensive research on the companies that are working on anti-CD19 antibody including the deals and acquisitions.

Report Coverage:

Clinical (Phase Products)

Non-clinical (Preclinical and Discovery)

Dormant and Discontinued

Companies Mentioned

CRISPR Therapeutics, Juno Therapeutics, MorphoSys, MacroGenics, TCR2 Therapeutics, Novimmune

Request Sample Report @ https://www.wiseguyreports.com/sample-request/3271728-anti-cd19-antibody-pipeline-analysis-2018

Table of Content:

Executive Summary

Overview of Anti-CD19 antibodies

Recent Trends

Pipeline Therapeutics

Therapeutics under Development by Companies

Late State Products

Product Description
Research and Development
Product Development Activities
Mid Stage Products

Product Description
Research and Development
Product Development Activities
Early Stage Products

Product Description
Research and Development
Product Development Activities
Therapeutic Assessment

Assessment by Route of Administration
Assessment by Phase & Route of Administration
Assessment by Molecule Type
Assessment by Phase & Molecule type
Collaborations and Acquisitions Details

Dormant Products

Discontinued Products

Appendix

Methodology

Disclaimer

Table 1: Products Under Development for anti-CD19 antibodies, 2018

Table 2: Products under Development by Companies, 2018

Table 3: Late Stage Products, 2018

Table 4: Mid Stage Products, 2018

Table 5: Early Stage Products, 2018

Table 6: Pre-Clinical and Discovery Products, 2018

Table 7: Assessment by Route of Administration, 2018

Table 8: Assessment by Stage and Route of Administration, 2018

Table 9: Assessment by Molecule Type, 2018

Table 10: Assessment by Stage and Molecule Type, 2018

Table 11: Comparative Analysis

Table 12: Dormant Products

Table 13: Discontinued Products

Figure 1: Products Under Development for anti-CD19 antibodies, 2018

Figure 2: Products under Development by Companies, 2018

Figure 3: Late Stage Products, 2018

Figure 4: Mid Stage Products, 2018

Figure 5: Early Stage Products, 2018

Figure 6: Pre-Clinical and Discovery Products, 2018

Figure 7: Assessment by Route of Administration, 2018

Figure 8: Assessment by Stage and Route of Administration, 2018

Figure 9: Assessment by Molecule Type, 2018

Figure 10: Assessment by Stage and Molecule Type, 2018

Figure 11: Comparative Analysis

Figure 12: Dormant Products

Figure 13: Discontinued Products

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/3271728-anti-cd19-antibody-pipeline-analysis-2018

Contact Us:

Norah Trent           

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US); +44 208 133 9349 (UK)

About Us:
Wise Guy Reports Is Part Of The Wise Guy Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe. Wise Guy Reports Features An Exhaustive List Of Market Research Reports From Hundreds Of Publishers Worldwide. We Boast A Database Spanning Virtually Every Market Category And An Even More Comprehensive Collection Of Market Research Reports Under These Categories And Sub-Categories.

Addres:
WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India
Phone :+91 841 198 5042

This release was published on openPR.